bullish
CHMP Meeting Update: 4 New Medicines Recommended For Approval, Reinstates Previous Leqembi Decision
334 Views03 Mar 2025 00:30
EMA’s CHMP recommended three new and one generic medicines for approval at its February 2025 meeting. The committee concluded that its positive opinion for Leqembi does not need to be updated.
What is covered in the Full Insight:
- CHMP February 2025 Meeting Outcomes
- New Medicines Recommended for Approval
- Extensions of Therapeutic Indications
- Re-examination Outcomes and Withdrawals
- Other Regulatory Updates
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 5-minute read)
Related Insights
More »Loading
Trending Collections
More »Loading
Trending Insights
More »Loading
Top Unpaywalled Insights
More »Loading
Discussions
(Paid Plans Only)
Top Quartile
Tina Banerjee
Global Healthcare Analyst
- CHMP Meeting Update: 4 New Medicines Recommended For Approval, Reinstates Previous Leqembi Decision03 Mar 2025
- CHMP Meeting Update: Eight New Medicines Recommended For Approval03 Feb 2025
x